Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

T-cell receptors engineered de novo for peptide specificity can mediate optimal T-cell activity without self cross-reactivity.

Sharma P, Harris DT, Stone JD, Kranz DM.

Cancer Immunol Res. 2019 Sep 23. pii: canimm.0035.2019. doi: 10.1158/2326-6066.CIR-19-0035. [Epub ahead of print]

PMID:
31548259
2.

Breaking tolerance with engineered class I antigen-presenting molecules.

Parks CA, Henning KR, Pavelko KD, Hansen MJ, Van Keulen VP, Reed BK, Stone JD, Schrum AG, Gil D, Kranz DM, Bordner AJ, Barry MA, Pease LR.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3136-3145. doi: 10.1073/pnas.1807465116. Epub 2019 Feb 6.

3.

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.

Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM.

Cancer Immunol Res. 2019 Jan;7(1):50-61. doi: 10.1158/2326-6066.CIR-18-0395. Epub 2018 Nov 13.

PMID:
30425106
4.

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.

Harris DT, Hager MV, Smith SN, Cai Q, Stone JD, Kruger P, Lever M, Dushek O, Schmitt TM, Greenberg PD, Kranz DM.

J Immunol. 2018 Feb 1;200(3):1088-1100. doi: 10.4049/jimmunol.1700236. Epub 2017 Dec 29.

5.

Subtle changes at the variable domain interface of the T-cell receptor can strongly increase affinity.

Sharma P, Kranz DM.

J Biol Chem. 2018 Feb 2;293(5):1820-1834. doi: 10.1074/jbc.M117.814152. Epub 2017 Dec 11.

6.

Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro.

Schmitt TM, Aggen DH, Ishida-Tsubota K, Ochsenreither S, Kranz DM, Greenberg PD.

Nat Biotechnol. 2017 Dec;35(12):1188-1195. doi: 10.1038/nbt.4004. Epub 2017 Nov 6.

7.

Recent advances in T-cell engineering for use in immunotherapy.

Sharma P, Kranz DM.

F1000Res. 2016 Sep 19;5. pii: F1000 Faculty Rev-2344. eCollection 2016. Review.

8.

Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex.

Harris DT, Wang N, Riley TP, Anderson SD, Singh NK, Procko E, Baker BM, Kranz DM.

J Biol Chem. 2016 Nov 18;291(47):24566-24578. Epub 2016 Sep 28.

9.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

10.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

11.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH.

Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.

12.

An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Geometry.

Harris DT, Singh NK, Cai Q, Smith SN, Vander Kooi C, Procko E, Kranz DM, Baker BM.

Structure. 2016 Jul 6;24(7):1142-1154. doi: 10.1016/j.str.2016.04.011. Epub 2016 May 26.

13.

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

Harris DT, Kranz DM.

Trends Pharmacol Sci. 2016 Mar;37(3):220-230. doi: 10.1016/j.tips.2015.11.004. Epub 2015 Dec 17. Review.

14.

Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity.

Adams JJ, Narayanan S, Birnbaum ME, Sidhu SS, Blevins SJ, Gee MH, Sibener LV, Baker BM, Kranz DM, Garcia KC.

Nat Immunol. 2016 Jan;17(1):87-94. doi: 10.1038/ni.3310. Epub 2015 Nov 2.

15.

Studies of the TLR4-associated protein MD-2 using yeast-display and mutational analyses.

Mattis DM, Chervin AS, Ranoa DR, Kelley SL, Tapping RI, Kranz DM.

Mol Immunol. 2015 Dec;68(2 Pt A):203-12. doi: 10.1016/j.molimm.2015.08.008. Epub 2015 Aug 28.

16.

A Multiplex Assay for Detection of Staphylococcal and Streptococcal Exotoxins.

Sharma P, Wang N, Chervin AS, Quinn CL, Stone JD, Kranz DM.

PLoS One. 2015 Aug 25;10(8):e0135986. doi: 10.1371/journal.pone.0135986. eCollection 2015.

17.

T Cell Receptor Engineering and Analysis Using the Yeast Display Platform.

Smith SN, Harris DT, Kranz DM.

Methods Mol Biol. 2015;1319:95-141. doi: 10.1007/978-1-4939-2748-7_6.

18.

TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.

Stone JD, Harris DT, Kranz DM.

Curr Opin Immunol. 2015 Apr;33:16-22. doi: 10.1016/j.coi.2015.01.003. Epub 2015 Jan 22. Review.

19.

Herman N. Eisen: Mentor to many.

Kranz DM, Sykulev Y.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1650-1. doi: 10.1073/pnas.1500050112. Epub 2015 Jan 23. No abstract available.

20.

Changing the peptide specificity of a human T-cell receptor by directed evolution.

Smith SN, Wang Y, Baylon JL, Singh NK, Baker BM, Tajkhorshid E, Kranz DM.

Nat Commun. 2014 Nov 7;5:5223. doi: 10.1038/ncomms6223.

21.

Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.

Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, Shisler JL, MacNeill AL, Roy EJ.

PLoS One. 2014 Oct 16;9(10):e109801. doi: 10.1371/journal.pone.0109801. eCollection 2014.

22.

A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Stone JD, Harris DT, Soto CM, Chervin AS, Aggen DH, Roy EJ, Kranz DM.

Cancer Immunol Immunother. 2014 Nov;63(11):1163-76. doi: 10.1007/s00262-014-1586-z. Epub 2014 Aug 1.

23.

TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility.

Hawse WF, De S, Greenwood AI, Nicholson LK, Zajicek J, Kovrigin EL, Kranz DM, Garcia KC, Baker BM.

J Immunol. 2014 Mar 15;192(6):2885-91. doi: 10.4049/jimmunol.1302953. Epub 2014 Feb 12.

24.

Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens.

Sharma P, Wang N, Kranz DM.

Toxins (Basel). 2014 Jan 28;6(2):556-74. doi: 10.3390/toxins6020556. Review.

25.

Characterization of the Staphylococcal enterotoxin A: Vβ receptor interaction using human receptor fragments engineered for high affinity.

Sharma P, Postel S, Sundberg EJ, Kranz DM.

Protein Eng Des Sel. 2013 Dec;26(12):781-9. doi: 10.1093/protein/gzt054. Epub 2013 Oct 27.

26.

The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system.

Narayanan S, Kranz DM.

J Biol Chem. 2013 Nov 1;288(44):31784-94. doi: 10.1074/jbc.M113.478412. Epub 2013 Sep 24.

27.

Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.

Stone JD, Kranz DM.

Front Immunol. 2013 Aug 21;4:244. doi: 10.3389/fimmu.2013.00244. eCollection 2013.

28.

Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.

Smith SN, Sommermeyer D, Piepenbrink KH, Blevins SJ, Bernhard H, Uckert W, Baker BM, Kranz DM.

J Mol Biol. 2013 Nov 15;425(22):4496-507. doi: 10.1016/j.jmb.2013.08.007. Epub 2013 Aug 14.

29.

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD.

Blood. 2013 Jul 18;122(3):348-56. doi: 10.1182/blood-2013-01-478164. Epub 2013 May 14.

30.

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H.

Cancer Cell. 2013 Apr 15;23(4):516-26. doi: 10.1016/j.ccr.2013.03.018.

31.

Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes.

Low JL, Naidoo A, Yeo G, Gehring AJ, Ho ZZ, Yau YH, Shochat SG, Kranz DM, Bertoletti A, Grotenbreg GM.

PLoS One. 2012;7(12):e51397. doi: 10.1371/journal.pone.0051397. Epub 2012 Dec 10.

32.

Novel platform for the detection of Staphylococcus aureus enterotoxin B in foods.

Tallent SM, Degrasse JA, Wang N, Mattis DM, Kranz DM.

Appl Environ Microbiol. 2013 Mar;79(5):1422-7. doi: 10.1128/AEM.02743-12. Epub 2012 Dec 14.

33.

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).

Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM.

Oncoimmunology. 2012 Sep 1;1(6):863-873.

34.

Engineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in rabbit models of disease.

Mattis DM, Spaulding AR, Chuang-Smith ON, Sundberg EJ, Schlievert PM, Kranz DM.

Protein Eng Des Sel. 2013 Feb;26(2):133-42. doi: 10.1093/protein/gzs094. Epub 2012 Nov 15.

35.

Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses.

Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, Kranz DM.

Gene Ther. 2013 Jun;20(6):634-44. doi: 10.1038/gt.2012.80. Epub 2012 Oct 11.

36.

Subtle changes in TCRα CDR1 profoundly increase the sensitivity of CD4 T cells.

Lynch JN, Donermeyer DL, Weber KS, Kranz DM, Allen PM.

Mol Immunol. 2013 Mar;53(3):283-94. doi: 10.1016/j.molimm.2012.08.020. Epub 2012 Sep 14.

37.

Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Stone JD, Chervin AS, Schreiber H, Kranz DM.

Biotechnol Prog. 2012 Nov-Dec;28(6):1588-97. doi: 10.1002/btpr.1631. Epub 2012 Oct 18.

38.

Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters.

Lu X, Gibbs JS, Hickman HD, David A, Dolan BP, Jin Y, Kranz DM, Bennink JR, Yewdell JW, Varma R.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15407-12. Epub 2012 Sep 4.

39.

MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.

Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM.

Cancer Immunol Immunother. 2013 Feb;62(2):359-69. doi: 10.1007/s00262-012-1336-z. Epub 2012 Aug 25.

40.

Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality.

Kohler PL, Greenwood SD, Nookala S, Kotb M, Kranz DM, Schlievert PM.

PLoS One. 2012;7(7):e41157. doi: 10.1371/journal.pone.0041157. Epub 2012 Jul 16.

41.

Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.

Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H.

Mol Ther. 2012 Mar;20(3):652-60. doi: 10.1038/mt.2011.286. Epub 2012 Jan 10.

42.

T cell receptor engineering.

Stone JD, Chervin AS, Aggen DH, Kranz DM.

Methods Enzymol. 2012;503:189-222. doi: 10.1016/B978-0-12-396962-0.00008-2.

PMID:
22230570
43.

Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs.

Stone JD, Artyomov MN, Chervin AS, Chakraborty AK, Eisen HN, Kranz DM.

J Immunol. 2011 Dec 15;187(12):6281-90. doi: 10.4049/jimmunol.1101734. Epub 2011 Nov 18.

44.

T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex.

Adams JJ, Narayanan S, Liu B, Birnbaum ME, Kruse AC, Bowerman NA, Chen W, Levin AM, Connolly JM, Zhu C, Kranz DM, Garcia KC.

Immunity. 2011 Nov 23;35(5):681-93. doi: 10.1016/j.immuni.2011.09.013.

45.

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF.

J Exp Med. 2011 Sep 26;208(10):2005-16. doi: 10.1084/jem.20101159. Epub 2011 Sep 19.

46.

Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM.

Gene Ther. 2012 Apr;19(4):365-74. doi: 10.1038/gt.2011.104. Epub 2011 Jul 14.

47.

Molecular basis of a million-fold affinity maturation process in a protein-protein interaction.

Bonsor DA, Postel S, Pierce BG, Wang N, Zhu P, Buonpane RA, Weng Z, Kranz DM, Sundberg EJ.

J Mol Biol. 2011 Aug 12;411(2):321-8. doi: 10.1016/j.jmb.2011.06.009. Epub 2011 Jun 12.

48.

Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, Macneill AL, Roy EJ.

Cancer Immunol Immunother. 2011 Oct;60(10):1461-72. doi: 10.1007/s00262-011-1045-z. Epub 2011 Jun 9.

49.

Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.

Stone JD, Aggen DH, Chervin AS, Narayanan S, Schmitt TM, Greenberg PD, Kranz DM.

J Immunol. 2011 May 1;186(9):5193-200. doi: 10.4049/jimmunol.1003755. Epub 2011 Mar 30.

50.

Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM.

Protein Eng Des Sel. 2011 Apr;24(4):361-72. doi: 10.1093/protein/gzq113. Epub 2010 Dec 14.

Supplemental Content

Loading ...
Support Center